TickerHumSide-by-side comparison
Amgen vs Bristol-Myers Squibb
As of Nov 11, 2026, P/E is 27.1x for Amgen vs 13.9x for Bristol-Myers Squibb; P/S is 6.5x for Amgen vs 2.6x for Bristol-Myers Squibb; revenue growth is 8.2% for Amgen vs 4.2% for Bristol-Myers Squibb; net margin is 24.1% for Amgen vs 18.5% for Bristol-Myers Squibb.
What stands out
- Bristol-Myers Squibb is cheaper on earnings: 13.9x P/E vs 27.1x for Amgen.
- Bristol-Myers Squibb carries less debt relative to equity: 1.79 vs 3.60 for Amgen.
Key metrics
| Metric | AMGN | BMY |
|---|---|---|
| Price | $468.11 | $62.91 |
| Market cap | $253.21B | $128.59B |
| P/E | 27.1x (#2) | 13.9x (#1) |
| P/S | 6.5x (#2) | 2.6x (#1) |
| Revenue growth | 8.2% (#1) | 4.2% (#2) |
| Operating margin | 32.4% (#1) | — |
| Net margin | 24.1% (#1) | 18.5% (#2) |
| Debt / equity | 3.60 (#2) | 1.79 (#1) |
| 1-year return | +39.2% (#1) | +28.2% (#2) |
| Research score | 68/100 (#2) | 69/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Amgen Inc. (AMGN) — Drug Manufacturers—General
- Bristol-Myers Squibb Company (BMY) — Drug Manufacturers—General